Summary: At Psych Congress 2024, Axsome Therapeutics will present new research on solriamfetol, focusing on its effectiveness for managing excessive daytime sleepiness and cognitive impairment in patients with obstructive sleep apnea (OSA) and narcolepsy. These studies, part of Axsome’s broader portfolio of CNS therapies, include data from real-world and clinical settings, emphasizing solriamfetol’s potential role in addressing both cognitive and sleep-related symptoms in these conditions.
Key Takeaways:
- Solriamfetol for Daytime Sleepiness: Axsome’s research highlights solriamfetol’s effectiveness in reducing excessive daytime sleepiness in OSA and narcolepsy patients, with insights from real-world studies.
- Cognitive Benefits: New data from clinical trials indicate solriamfetol may improve cognitive function in patients with impaired cognition related to OSA and narcolepsy.
- Broader CNS Portfolio: In addition to solriamfetol, Axsome will showcase other product candidates aimed at managing major depressive disorder and Alzheimer’s-related agitation.
Axsome Therapeutics Inc, a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced seven presentations, including three related to solriamfetol in obstructive sleep apnea (OSA) and narcolepsy, from its portfolio of neuroscience products and product candidates at Psych Congress 2024, being held Oct 29 to Nov 2, 2024, in Boston.
Sleep medicine presentations will discuss solriamfetol for excessive daytime sleepiness in patients with narcolepsy and OSA, as well as the effects of solriamfetol on cognition in OSA with excessive daytime sleepiness and impaired cognition and on cognition in patients with excessive daytime sleepiness association with narcolepsy.
Solriamfetol, sold under the brand name Sunosi, is a wakefulness-promoting medication used in the treatment of excessive sleepiness related to narcolepsy and sleep apnea.
The presentation details are as follows:
Title: Solriamfetol for Excessive Daytime Sleepiness in Patients with Narcolepsy and OSA Reporting Anxiety and Depression in the Real-World SURWEY Study
Presentation Date and Time: Thursday, Oct 31, 1:30 – 3 pm and Friday, Nov 1, 1:30 – 3 pm ET
Lead Author: Ulf Kallweit, MD, assistant professor of neurology at the University Witten/Herdecke, Germany
Poster Number: 20
Title: Effects of Solriamfetol on Cognition in Obstructive Sleep Apnea with Excessive Daytime Sleepiness and Impaired Cognition in the SHARP Clinical Trial
Presentation Date and Time: Thursday, Oct 31, 1:30 – 3 pm and Friday, Nov 1, 1:30 – 3 pm ET
Lead Author: Yaroslav Winter, MD, Mainz Comprehensive Epilepsy and Sleep Medicine Center, department of neurology, Johannes Gutenberg-University, Mainz, Germany
Poster Number: 92
Title: Effects of Solriamfetol on Cognition in Patients with Excessive Daytime Sleepiness Associated with Narcolepsy in the Real-World SURWEY Study
Presentation Date and Time: Thursday, Oct 31, 1:30 – 3 pm and Friday, Nov 1, 1:30 – 3 pm ET
Lead Author: Yaroslav Winter, MD, Mainz Comprehensive Epilepsy and Sleep Medicine Center, department of neurology, Johannes Gutenberg-University, Mainz, Germany
Poster Number: 164
Other presentations from Axsome will focus on product and product candidates in major depressive disorder and Alzheimer’s disease agitation.
Photo caption: Sunosi (solriamfetol)
File photo/Axsome
Leave a Reply